Clinical trials
Gynaecological Oncology clinical trials
Below are recruiting gynaecological oncology clinical trials, each written for real people, not researchers. We’re tracking 7 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07210164Recruiting
Pre-surgery wellness program for gynecologic cancer surgery
This trial tests whether a pre-surgery wellness program (pre-habilitation) within an enhanced recovery protocol helps women recover better after surgery for endometrial, ovarian, or cervical cancer. It is designed for women who are having open abdominal surgery (laparotomy).
ThessalonikiAges 18–85 - NCT05896020RecruitingPhase 2
Test drug SHR-A1811 for gynecologic cancers
This Phase 2 trial tests SHR-A1811, a cancer medicine, in people with advanced or returning cervical, ovarian, or endometrial cancer. It may help shrink tumors, depending on whether you meet study safety and eligibility requirements.
Jinan, ShandongAges 18–75 - NCT07546825Recruiting
Minimally invasive versus open surgery for endometrial cancer staging
This trial compares two surgical approaches for treating endometrial cancer: traditional open surgery (laparotomy) versus minimally invasive keyhole surgery (laparoscopy). The goal is to determine which method is safer and more effective for removing the uterus, ovaries, and lymph nodes while staging the cancer.
AsyutAges Any age - NCT05142150Recruiting
Care and expectations study for advanced gynecologic cancer
This trial looks at what patients with advanced gynecologic cancer expect from care, and how well their care needs are being met. It uses questionnaires to learn what support is most helpful, especially near the end of life.
OsloAges 18 years+ - NCT05460000RecruitingPhase 2
Niraparib after early ovarian cancer chemo—short vs long
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
InnsbruckAges 18 years+ - NCT05574673Recruiting
Study of DNA repair traits in ovarian cancer patients
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
København Ø, Region SjællandAges 18–100 - NCT07087366Recruiting
Enhanced recovery after gynecologic cancer surgery
This trial tests a program to help women recover faster after surgery for cervical, uterine, or ovarian cancer. It focuses on improving recovery steps to reduce hospital stay and make the process smoother.
DhakaAges 18–70
Hear when a new Gynaecological Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gynaecological oncology?
- Yes. Clin2 currently lists 7 recruiting gynaecological oncology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gynaecological oncology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gynaecological oncology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.